These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 647632)
1. Biologic markers in breast carcinoma. IV. Serum fucose-protein ratio. Comparisons with carcinoembryonic antigen and human chorionic gonadotrophin. Waalkes TP; Gehrke CW; Tormey DC; Woo KB; Kuo KC; Synder J; Hansen H Cancer; 1978 May; 41(5):1871-82. PubMed ID: 647632 [TBL] [Abstract][Full Text] [Related]
2. Serum protein-bound carbohydrates for following the course of disease in patients with metastatic breast carcinoma. Waalkes TP; Mrochek JE; Dinsmore SR; Tormey DC J Natl Cancer Inst; 1978 Sep; 61(3):703-7. PubMed ID: 278847 [TBL] [Abstract][Full Text] [Related]
3. Serum tumor markers in metastatic breast cancer and course of disease. Caffier H; Brandau H Cancer Detect Prev; 1983; 6(4-5):451-7. PubMed ID: 6197167 [TBL] [Abstract][Full Text] [Related]
4. Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides. Tormey DC; Waalkes TP; Ahmann D; Gehrke CW; Zumwatt RW; Snyder J; Hansen H Cancer; 1975 Apr; 35(4):1095-100. PubMed ID: 1116102 [TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen and L-fucose in malignant and benign mammary disease. Wilkinson EJ; Hause LL; Sasse EA; Pattillo RA; Milbrath JR; Lewis JD Am J Clin Pathol; 1980 May; 73(5):669-75. PubMed ID: 7377133 [TBL] [Abstract][Full Text] [Related]
6. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients. Paulick R; Caffier H; Paulick M Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016 [TBL] [Abstract][Full Text] [Related]
7. Beta-human chorionic gonadotrophin and carcino-embryonic antigen in the management of ovarian carcinoma. Stone M; Bagshawe KD; Kardana A; Searle F; Dent J Br J Obstet Gynaecol; 1977 May; 84(5):375-9. PubMed ID: 889730 [TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen and human chorionic gonadotrophin in breast carcinoma and prostatic specific acid phosphatase in prostate carcinoma. Arora B; Chhabra A; Yadav MS; Arora DR Indian J Pathol Microbiol; 1990 Jul; 33(3):235-8. PubMed ID: 1965432 [TBL] [Abstract][Full Text] [Related]
9. [The significance of the measurement of a serum gonadotropin-like substance in gastric cancer]. Yonemura Y; Sawa T; Hashimoto T; Shima Y; Miyazaki I; Miwa K Nihon Geka Gakkai Zasshi; 1985 Jun; 86(6):680-5. PubMed ID: 4033623 [TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen and other tumor markers in tissue and serum or plasma of patients with primary mammary carcinoma. Wahren B; Lidbrink E; Wallgren A; Eneroth P; Zajicek J Cancer; 1978 Oct; 42(4):1870-8. PubMed ID: 361213 [TBL] [Abstract][Full Text] [Related]
11. Clinical correlation between CEA and breast cancer. Tormey DC; Waalkes TP Cancer; 1978 Sep; 42(3 Suppl):1507-11. PubMed ID: 709522 [TBL] [Abstract][Full Text] [Related]
12. A new biomarker in monitoring breast cancer: CA 549. Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875 [TBL] [Abstract][Full Text] [Related]
13. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. Dexeus F; Logothetis C; Hossan E; Samuels ML J Urol; 1986 Aug; 136(2):403-7. PubMed ID: 2426474 [TBL] [Abstract][Full Text] [Related]
14. Human chorionic gonadotrophins (hCG) in non-trophoblastic neoplasms. Assessment of abnormalities of hCG and CEA in bronchogenic and digestive neoplasms. Gailani S; Chu TM; Nussbaum A; Ostrander M; Christoff N Cancer; 1976 Oct; 38(4):1684-6. PubMed ID: 991086 [TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen. Purnell DM; Heatfield BM; Trump BF Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163 [TBL] [Abstract][Full Text] [Related]
16. Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen. Silva JS; Leight GS; Haagensen DE; Tallos PB; Cox EB; Dilley WG; Wells SA Cancer; 1982 Mar; 49(6):1236-42. PubMed ID: 6174201 [TBL] [Abstract][Full Text] [Related]
17. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen in patients with breast cancer: an adjunctive tool to monitor response and therapy. Falkson HC; Van Der Watt JJ; Portugal MA; Pitout MJ; Falkson G Cancer; 1978 Sep; 42(3):1308-13. PubMed ID: 698917 [TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma. Haagensen DE; Kister SJ; Panick J; Giannola J; Hansen HJ; Wells SA Cancer; 1978 Sep; 42(3 Suppl):1646-52. PubMed ID: 709529 [TBL] [Abstract][Full Text] [Related]
20. Biochemical markers in cancer of the breast. Tormey DC; Waalkes TP Recent Results Cancer Res; 1976; (57):78-94. PubMed ID: 796922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]